Pediatrix Medical Group, Inc. (MD)
(Delayed Data from NYSE)
$9.03 USD
0.00 (0.00%)
Updated Apr 22, 2024 04:00 PM ET
After-Market: $9.02 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.03 USD
0.00 (0.00%)
Updated Apr 22, 2024 04:00 PM ET
After-Market: $9.02 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Zacks News
Pediatrix Medical (MD) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Pediatrix Medical's (MD) fourth-quarter results are likely to reflect higher operating expenses and patient volume growth.
Earnings Preview: Pediatrix Medical Group (MD) Q4 Earnings Expected to Decline
by Zacks Equity Research
Pediatrix Medical Group (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for December 23rd
by Zacks Equity Research
SGRP, LFCR and MD have been added to the Zacks Rank #5 (Strong Sell) List on December 23, 2022.
Pediatrix (MD) Down 19% Since Q3 Earnings & Revenue Miss
by Zacks Equity Research
Pediatrix's (MD) Q3 results reflect volume constraints and an elevated expense level. Adjusted EBITDA is now expected within $240-$245 million, down from the earlier view of $260-$270 million.
Pediatrix Medical Group (MD) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of -24.53% and 4.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Humana (HUM) Sustain Its Earnings Beat Streak in Q3?
by Zacks Equity Research
Humana's (HUM) Q3 results are expected to reflect growing premiums, attributable to its Medicare Advantage and Medicaid businesses. However, elevated marketing costs might have strained its margins.
NovoCure (NVCR) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 16.67% and 2.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Healthcare Stocks Set to Outshine Q3 Earnings Estimates
by Kaibalya Pravo Dey
Recovering volumes, improved admissions, growing health awareness and wide utilization of technologies in the third quarter are expected to have aided healthcare stocks like Humana (HUM), Teladoc (TDOC) and Pediatrix Medical (MD).
Can Rising Visits Help Teladoc (TDOC) Beat on Earnings in Q3?
by Zacks Equity Research
The third-quarter results of Teladoc (TDOC) are likely to reflect a rise in Access Fees and Visit Fee revenues.
Earnings Preview: Avantor, Inc. (AVTR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Avantor, Inc. (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pediatrix Medical Group (MD) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Pediatrix Medical Group (MD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Icon PLC (ICLR): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
Icon PLC (ICLR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Elevance Health (ELV) to Post Q3 Earnings: A Beat in the Cards?
by Zacks Equity Research
Elevance Health's (ELV) third-quarter results are likely to reflect improved premiums and net investment income.
Here's Why Pediatrix Medical Group (MD) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MD or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. GDRX: Which Stock Is the Better Value Option?
The Beauty Health Company (SKIN) Stock Jumps 11.4%: Will It Continue to Soar?
by Zacks Equity Research
The Beauty Health Company (SKIN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Pediatrix (MD) Up 8% Since Q2 Earnings Release, Revenues Up Y/Y
by Zacks Equity Research
Pediatrix's (MD) second-quarter results reflect growth in patient volumes. Adjusted EBITDA is expected within $260-$270 million for 2022.
Mednax (MD) Q2 Earnings Match Estimates
by Zacks Equity Research
Mednax (MD) delivered earnings and revenue surprises of 0% and 1.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Mednax (MD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia Healthcare (ACHC) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of 9.09% and 0.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Acadia Healthcare, Pediatrix Medical, Tenet Healthcare and Discover Financial Services
by Zacks Equity Research
Acadia Healthcare, Pediatrix Medical, Tenet Healthcare and Discover Financial Services are part of Zacks Industry Outlook article.
Zacks.com featured highlights include Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics and Oncolytics Biotech
by Zacks Equity Research
Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics, and Oncolytics Biotech are part of Zacks Screen of the week article.
2 Top Hospital Stocks to Buy Despite Industry Headwinds
by Kaibalya Pravo Dey
Rising supplies expense, wages and benefits, and other operating costs are lowering margins for the Zacks Medical-Hospital industry players. However, Acadia Healthcare and Pediatrix Medical are poised to win big with recovering patient volumes.
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap Oncolytics Biotech (ONCY), Pediatrix Medical Group Inc (MD), Boot Barn (BOOT), Canada Goose (GOOS) and Leap Therapeutics (LPTX).
Why Pediatrix Medical (MD) is a Solid Bet for Your Portfolio
by Zacks Equity Research
Pediatrix Medical (MD) is expected to boost its services across maternal-fetal medicine, neonatology and obstetrics, plus 18 pediatric subspecialty offerings.